1,3,4,5-tetramethyl-2[(2-oxopropyl)thio]imidazolium chloride | 134218-50-1

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 1,3,4,5-tetramethyl-2[(2-oxopropyl)thio]imidazolium chloride
• 英文别名: 1-(1,3,4,5-Tetramethylimidazol-1-ium-2-yl)sulfanylpropan-2-one;chloride
• CAS: 134218-50-1
• 化学式: C₁₀H₁₇N₂OS*Cl
• 分子量: 248.777
• InChiKey: YWTXHMSMJQIXSG-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -1.85
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  51.2
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Tissue transglutaminase inhibitors
  申请人：Stein L. Ross

  公开号：US20060183759A1

  公开（公告）日：2006-08-17

  The present invention provides novel compounds and methods useful for treating transglutaminase associated disorders such as celiac spru, Alzheimer's disease and Huntington's disease. Certain compounds of the invention are tissue transglutaminase inhibitors that comprise thiophene moieties. Methods of the invention include treatment of transglutaminase associated disorders with inhibitors of transglutaminase.

  本发明提供了一种治疗转酰胺酶相关疾病的新化合物和方法，例如腹泻性脆皮病、阿尔茨海默病和亨廷顿病。本发明的某些化合物是组织转酰胺酶抑制剂，包括噻吩基团。本发明的方法包括使用转酰胺酶抑制剂治疗转酰胺酶相关疾病。
• Certain imidazole compounds as transglutaminase inhibitors
  申请人：MERCK & CO. INC.

  公开号：EP0411701A2

  公开（公告）日：1991-02-06

  A method for inhibiting transglutaminase activity, especially Factor XIIIa activity with certain imidazole compounds is described. Also described are compositions suitable for use in inhibiting transglutaminase activity.

  描述了一种用某些咪唑化合物抑制转谷氨酰胺酶活性，特别是因子 XIIIa 活性的方法。此外，还介绍了适用于抑制转谷氨酰胺酶活性的组合物。
• Methods and compositions for the treatment of parkinson's disease and other alpha-synucleinopathies
  申请人：Mouradian Maral M.

  公开号：US20060211624A1

  公开（公告）日：2006-09-21

  The present invention provides novel methods for the treatment of Parkinson's disease and other α-synucleinopathies. The methods of the invention include treatment with inhibitors of transglutaminase, which can inhibit aggregation of α-synuclein. Also provided are screening assays for novel inhibitors of transglutaminase which may be used in the treatment of Parkinson's disease and other α-synucleinopathies.

  本发明提供了治疗帕金森病和其他α-突触核蛋白病的新方法。本发明的方法包括使用转谷氨酰胺酶抑制剂进行治疗，这种抑制剂可以抑制α-突触核蛋白的聚集。本发明还提供了新型转谷氨酰胺酶抑制剂的筛选方法，可用于治疗帕金森病和其他α-突触核蛋白病。
• METHODE ZUR DIFFERENZIERUNG VON FAKTOR XIII- GEGENÜBER FIBRINOGEN- MANGELZUSTÄNDEN UNTER EINSATZ THROMBELASTOGRAPHISCHER TECHNIKEN
  申请人：CSL Behring GmbH

  公开号：EP1851552B1

  公开（公告）日：2014-04-23
• Methode zur Feststellung von von Faktor XIII-Mangelzuständen unter Einsatz thrombelastographischer Techniken
  申请人：CSL Behring GmbH

  公开号：EP2474830B1

  公开（公告）日：2014-09-24